{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:41:08Z","timestamp":1785526868740,"version":"3.56.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Rostock"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Achieving a balance between efficacy and side effects is essential for the success of new combinatorial cancer therapies. This study investigated the impact of adding BKM120, a PI3K inhibitor, to a dual regimen consisting of BI-3406, a KRAS\/SOS1 inhibitor, and trametinib, a MEK inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The therapeutic effects of these drug combinations were evaluated in the pancreatic cancer cell line 6606PDA using both monolayer and three-dimensional cultures. Additionally, their efficacy and potential side effects were assessed in vivo using a syngeneic orthotopic mouse model of pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>In vitro<\/jats:italic>\n                      studies demonstrated that the addition of BKM120 to BI-3406 and trametinib significantly reduced cell viability in both monolayer and three-dimensional cultures. However, in a syngeneic pancreatic cancer mouse model, the triple therapy failed to significantly improve survival outcome compared to the dual therapy. Tumor weights were unaffected in female mice, while a minor, non-significant reduction was observed in male mice. This was accompanied by a slight, non-significant decrease in cancer cell proliferation. In the triple therapy group,\n                      <jats:italic>Cdkn2a<\/jats:italic>\n                      expression in tumors, a marker for senescence, remained largely unchanged. However, PD-L1 was significantly reduced in males, and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell infiltration was notably enhanced in females. Importantly, the triple therapy demonstrated several concerning drawbacks.\n                    <\/jats:p>\n                    <jats:p>It significantly increased lung metastases in female mice, reduced lymphocyte and erythrocyte counts, and elevated C-peptide concentrations in both sexes.<\/jats:p>\n                    <jats:p>Furthermore, behavioral analysis indicated a significant decline in burrowing and nesting activities among female mice during specific experimental phases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The addition of BKM120 to the combination of BI-3406 and trametinib provides minimal therapeutic benefit while introducing significant adverse effects, underscoring the need for caution when considering clinical applications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16409-0","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:19:28Z","timestamp":1783081168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Benefits and challenges of adding BKM120 to a BI-3406 plus trametinib combination therapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Benjamin","family":"Schulz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Rabierad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Imran","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Murua Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Vollmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Zechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"16409_CR1","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3389\/fonc.2019.00965","volume":"9","author":"RC Gimple","year":"2019","unstructured":"Gimple RC, Wang X. RAS: striking at the core of the oncogenic circuitry. Front Oncol. 2019;9:965. https:\/\/doi.org\/10.3389\/fonc.2019.00965.","journal-title":"Front Oncol"},{"key":"16409_CR2","doi-asserted-by":"publisher","first-page":"176727","DOI":"10.1016\/j.ejphar.2024.176727","volume":"979","author":"MA Hossain","year":"2024","unstructured":"Hossain MA. Targeting the RAS upstream and downstream signaling pathway for cancer treatment. Eur J Pharmacol. 2024;979:176727. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176727.","journal-title":"Eur J Pharmacol"},{"key":"16409_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","volume":"21","author":"C Zhu","year":"2022","unstructured":"Zhu C, Guan X, Zhang X, Luan X, Song Z, Cheng X, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022;21:159. https:\/\/doi.org\/10.1186\/s12943-022-01629-2.","journal-title":"Mol Cancer"},{"key":"16409_CR4","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","volume":"28","author":"EC Nakajima","year":"2022","unstructured":"Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, et al. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res. 2022;28:1482\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3074.","journal-title":"Clin Cancer Res"},{"key":"16409_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2174\/0929867330666230330122000","volume":"31","author":"SK De","year":"2024","unstructured":"De SK. First approval of adagrasib for the treatment of non-small cell lung cancer harboring a KRASG12C Mutation. Curr Med Chem. 2024;31:266\u201372. https:\/\/doi.org\/10.2174\/0929867330666230330122000.","journal-title":"Curr Med Chem"},{"key":"16409_CR6","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1245\/s10434-021-11081-z","volume":"29","author":"S Shoucair","year":"2022","unstructured":"Shoucair S, Habib JR, Pu N, Kinny-K\u00f6ster B, van Ooston AF, Javed AA, et al. Comprehensive analysis of somatic mutations in driver genes of resected pancreatic ductal adenocarcinoma reveals KRAS G12D and mutant TP53 combination as an independent predictor of clinical outcome. Ann Surg Oncol. 2022;29:2720\u201331. https:\/\/doi.org\/10.1245\/s10434-021-11081-z.","journal-title":"Ann Surg Oncol"},{"key":"16409_CR7","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/1535-7163.MCT-23-0870","volume":"23","author":"N Sudhakar","year":"2024","unstructured":"Sudhakar N, Yan L, Qiryaqos F, Engstrom LD, Laguer J, Calinisan A, et al. The SOS1 inhibitor MRTX0902 blocks KRAS activation and demonstrates antitumor activity in cancers dependent on KRAS Nucleotide loading. Mol Cancer Ther. 2024;23:1418\u201330. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0870.","journal-title":"Mol Cancer Ther"},{"key":"16409_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","volume":"11","author":"MH Hofmann","year":"2021","unstructured":"Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, et al. BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov. 2021;11:142\u201357. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0142.","journal-title":"Cancer Discov"},{"key":"16409_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","volume":"577","author":"JY Xue","year":"2020","unstructured":"Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577:421\u20135. https:\/\/doi.org\/10.1038\/s41586-019-1884-x.","journal-title":"Nature"},{"key":"16409_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, et al. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discov. 2020;10:54\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1167.","journal-title":"Cancer Discov"},{"key":"16409_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/2159-8290.CD-20-1616","volume":"11","author":"NS Akhave","year":"2021","unstructured":"Akhave NS, Biter AB, Hong DS. Mechanisms of resistance to KRASG12C-targeted therapy. Cancer Discov. 2021;11:1345\u201352. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1616.","journal-title":"Cancer Discov"},{"key":"16409_CR12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41568-024-00679-6","volume":"24","author":"N Perurena","year":"2024","unstructured":"Perurena N, Situ L, Cichowski K. Combinatorial strategies to target RAS-driven cancers. Nat Rev Cancer. 2024;24:316\u201337. https:\/\/doi.org\/10.1038\/s41568-024-00679-6.","journal-title":"Nat Rev Cancer"},{"key":"16409_CR13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8:455. https:\/\/doi.org\/10.1038\/s41392-023-01705-z.","journal-title":"Signal Transduct Target Ther"},{"key":"16409_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2213329","volume":"389","author":"PK Brastianos","year":"2023","unstructured":"Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, et al. BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas. N Engl J Med. 2023;389:118\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2213329.","journal-title":"N Engl J Med"},{"key":"16409_CR15","doi-asserted-by":"publisher","first-page":"e28973","DOI":"10.1371\/journal.pone.0028973","volume":"6","author":"M Atefi","year":"2011","unstructured":"Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT\/mTOR pathway. PLoS ONE. 2011;6:e28973. https:\/\/doi.org\/10.1371\/journal.pone.0028973.","journal-title":"PLoS ONE"},{"key":"16409_CR16","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dr\u00e9no B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867\u201376. https:\/\/doi.org\/10.1056\/NEJMoa1408868.","journal-title":"N Engl J Med"},{"key":"16409_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184467","author":"Y Ma","year":"2022","unstructured":"Ma Y, Schulz B, Trakooljul N, Al Ammar M, Sekora A, Sender S, et al. Inhibition of KRAS, MEK and PI3K demonstrate synergistic anti-tumor effects in pancreatic ductal adenocarcinoma cell lines. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14184467.","journal-title":"Cancers (Basel)"},{"key":"16409_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101901","author":"B Schulz","year":"2024","unstructured":"Schulz B, Leitner E, Schreiber T, Lindner T, Schwarz R, Aboutara N, et al. Sex matters-insights from testing drug efficacy in an animal model of pancreatic cancer. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16101901.","journal-title":"Cancers (Basel)"},{"key":"16409_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1535-6108(03)00309-X","volume":"4","author":"SR Hingorani","year":"2003","unstructured":"Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437\u201350. https:\/\/doi.org\/10.1016\/S1535-6108(03)00309-X.","journal-title":"Cancer Cell"},{"key":"16409_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/nprot.2006.170","volume":"1","author":"RMJ Deacon","year":"2006","unstructured":"Deacon RMJ. Assessing nest building in mice. Nat Protoc. 2006;1:1117\u20139. https:\/\/doi.org\/10.1038\/nprot.2006.170.","journal-title":"Nat Protoc"},{"key":"16409_CR21","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1093\/neuonc\/noad117","volume":"25","author":"EK Noch","year":"2023","unstructured":"Noch EK, Palma LN, Yim I, Bullen N, Qiu Y, Ravichandran H, et al. Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma. Neuro Oncol. 2023;25:2165\u201376. https:\/\/doi.org\/10.1093\/neuonc\/noad117.","journal-title":"Neuro Oncol"},{"key":"16409_CR22","doi-asserted-by":"publisher","unstructured":"Siska W, Schultze AE, Ennulat D, Biddle K, Logan M, Adedeji AO, et al. Scientific and regulatory policy committee points to consider: integration of clinical pathology data with anatomic pathology data in nonclinical toxicology studies. Vet Clin Pathol. 2022;51:311\u201329. https:\/\/doi.org\/10.1111\/vcp.13167.","DOI":"10.1111\/vcp.13167"},{"key":"16409_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ph18060848","author":"D Lev\u00eaque","year":"2025","unstructured":"Lev\u00eaque D. Improving the dosing schedules of targeted anticancer agents. Pharmaceuticals (Basel). 2025. https:\/\/doi.org\/10.3390\/ph18060848.","journal-title":"Pharmaceuticals (Basel)"},{"key":"16409_CR24","doi-asserted-by":"publisher","first-page":"891383","DOI":"10.3389\/fonc.2022.891383","volume":"12","author":"MI Abu Zaid","year":"2022","unstructured":"Abu Zaid MI, Radovich M, Althouse S, Liu H, Spittler AJ, Solzak J, et al. A phase II study of buparlisib in relapsed or refractory thymomas. Front Oncol. 2022;12:891383. https:\/\/doi.org\/10.3389\/fonc.2022.891383.","journal-title":"Front Oncol"},{"key":"16409_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13058-020-01354-y","volume":"22","author":"AC Garrido-Castro","year":"2020","unstructured":"Garrido-Castro AC, Saura C, Barroso-Sousa R, Guo H, Ciruelos E, Bermejo B, et al. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2020;22:120. https:\/\/doi.org\/10.1186\/s13058-020-01354-y.","journal-title":"Breast Cancer Res"},{"key":"16409_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semcancer.2019.08.019","volume":"60","author":"C D\u2019Alterio","year":"2020","unstructured":"D\u2019Alterio C, Scala S, Sozzi G, Roz L, Bertolini G. Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Semin Cancer Biol. 2020;60:351\u201361. https:\/\/doi.org\/10.1016\/j.semcancer.2019.08.019.","journal-title":"Semin Cancer Biol"},{"key":"16409_CR27","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1158\/1535-7163.MCT-17-0207","volume":"16","author":"S Galb\u00e1n","year":"2017","unstructured":"Galb\u00e1n S, Apfelbaum AA, Espinoza C, Heist K, Haley H, Bedi K, et al. A bifunctional MAPK\/PI3K antagonist for inhibition of tumor growth and metastasis. Mol Cancer Ther. 2017;16:2340\u201350. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0207.","journal-title":"Mol Cancer Ther"},{"key":"16409_CR28","doi-asserted-by":"publisher","first-page":"38755","DOI":"10.18632\/oncotarget.16333","volume":"8","author":"B Li","year":"2017","unstructured":"Li B, Xu WW, Lam AKY, Wang Y, Hu H-F, Guan XY, et al. Significance of PI3K\/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy. Oncotarget. 2017;8:38755\u201366. https:\/\/doi.org\/10.18632\/oncotarget.16333.","journal-title":"Oncotarget"},{"key":"16409_CR29","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41467-024-45324-w","volume":"15","author":"Q Liu","year":"2024","unstructured":"Liu Q, Adhikari E, Lester DK, Fang B, Johnson JO, Tian Y, et al. Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation. Nat Commun. 2024;15:1148. https:\/\/doi.org\/10.1038\/s41467-024-45324-w.","journal-title":"Nat Commun"},{"key":"16409_CR30","doi-asserted-by":"publisher","first-page":"110987","DOI":"10.1016\/j.celrep.2022.110987","volume":"39","author":"J-J Tang","year":"2022","unstructured":"Tang J-J, Pan Y-F, Chen C, Cui X-L, Yan Z-J, Zhou D-X, et al. Androgens drive sexual dimorphism in liver metastasis by promoting hepatic accumulation of neutrophils. Cell Rep. 2022;39:110987. https:\/\/doi.org\/10.1016\/j.celrep.2022.110987.","journal-title":"Cell Rep"},{"key":"16409_CR31","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41416-020-0913-8","volume":"123","author":"AL Ray","year":"2020","unstructured":"Ray AL, Nofchissey RA, Khan MA, Reidy MA, Lerner MR, Wu X, et al. The role of sex in the innate and adaptive immune environment of metastatic colorectal cancer. Br J Cancer. 2020;123:624\u201332. https:\/\/doi.org\/10.1038\/s41416-020-0913-8.","journal-title":"Br J Cancer"},{"key":"16409_CR32","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00262-020-02643-3","volume":"69","author":"PP Dakup","year":"2020","unstructured":"Dakup PP, Porter KI, Little AA, Zhang H, Gaddameedhi S. Sex differences in the association between tumor growth and T cell response in a melanoma mouse model. Cancer Immunol Immunother. 2020;69:2157\u201362. https:\/\/doi.org\/10.1007\/s00262-020-02643-3.","journal-title":"Cancer Immunol Immunother"},{"key":"16409_CR33","doi-asserted-by":"publisher","first-page":"eabq2630","DOI":"10.1126\/sciimmunol.abq2630","volume":"7","author":"H Kwon","year":"2022","unstructured":"Kwon H, Schafer JM, Song N-J, Kaneko S, Li A, Xiao T, et al. Androgen conspires with the CD8\u2009+\u2009T cell exhaustion program and contributes to sex bias in cancer. Sci Immunol. 2022;7:eabq2630. https:\/\/doi.org\/10.1126\/sciimmunol.abq2630.","journal-title":"Sci Immunol"},{"key":"16409_CR34","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1158\/0008-5472.CAN-22-2405","volume":"83","author":"X Zhang","year":"2023","unstructured":"Zhang X, Cheng L, Gao C, Chen J, Liao S, Zheng Y, et al. Androgen signaling contributes to sex differences in cancer by inhibiting NF-\u03baB activation in T cells and suppressing antitumor immunity. Cancer Res. 2023;83:906\u201321. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-2405.","journal-title":"Cancer Res"},{"key":"16409_CR35","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.immuni.2022.05.012","volume":"55","author":"C Yang","year":"2022","unstructured":"Yang C, Jin J, Yang Y, Sun H, Wu L, Shen M, et al. Androgen receptor-mediated CD8\u2009+\u2009T cell stemness programs drive sex differences in antitumor immunity. Immunity. 2022;55:1268\u2013e12839. https:\/\/doi.org\/10.1016\/j.immuni.2022.05.012.","journal-title":"Immunity"},{"key":"16409_CR36","doi-asserted-by":"publisher","first-page":"e236324","DOI":"10.1001\/jamanetworkopen.2023.6324","volume":"6","author":"T Bla\u017eek","year":"2023","unstructured":"Bla\u017eek T, Petr\u00e1\u0161 M, Knybel L, Cvek J, Soumarov\u00e1 R. Programmed cell death ligand 1 expression on immune cells and survival in patients with nonmetastatic head and neck cancer: a systematic review and meta-analysis. JAMA Netw Open. 2023;6:e236324. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.6324.","journal-title":"JAMA Netw Open"},{"key":"16409_CR37","doi-asserted-by":"publisher","unstructured":"Kim Y, Wen X, Cho NY, Kang GH. Intratumoral immune cells expressing PD-1\/PD-L1 and their prognostic implications in cancer: a meta-analysis. Int J Biol Markers. 2018;1724600818770941. https:\/\/doi.org\/10.1177\/1724600818770941.","DOI":"10.1177\/1724600818770941"},{"key":"16409_CR38","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00262-022-03309-y","volume":"72","author":"LP Mocan","year":"2023","unstructured":"Mocan LP, Craciun R, Grapa C, Melincovici CS, Rusu I, Al Hajjar N, et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma. Cancer Immunol Immunother. 2023;72:1003\u201314. https:\/\/doi.org\/10.1007\/s00262-022-03309-y.","journal-title":"Cancer Immunol Immunother"},{"key":"16409_CR39","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.2217\/fon-2021-0092","volume":"17","author":"Q Zhong","year":"2021","unstructured":"Zhong Q, Shou J, Ying J, Ling Y, Yu Y, Shen Z, et al. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma. Future Oncol. 2021;17:2893\u2013905. https:\/\/doi.org\/10.2217\/fon-2021-0092.","journal-title":"Future Oncol"},{"key":"16409_CR40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI191943","author":"R Maddipati","year":"2025","unstructured":"Maddipati R. Metastatic heterogeneity in pancreatic cancer: mechanisms and opportunities for targeted intervention. J Clin Invest. 2025. https:\/\/doi.org\/10.1172\/JCI191943.","journal-title":"J Clin Invest"},{"key":"16409_CR41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.canlet.2015.04.028","volume":"364","author":"W Yao","year":"2015","unstructured":"Yao W, Yue P, Zhang G, Owonikoko TK, Khuri FR, Sun S-Y. Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K\/Akt signaling in human lung cancer cells. Cancer Lett. 2015;364:70\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2015.04.028.","journal-title":"Cancer Lett"},{"key":"16409_CR42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3892\/or.2016.4770","volume":"36","author":"Z-B Jiang","year":"2016","unstructured":"Jiang Z-B, Huang J, Xie C, Li X, Liu L, He J, et al. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations. Oncol Rep. 2016;36:365\u201375. https:\/\/doi.org\/10.3892\/or.2016.4770.","journal-title":"Oncol Rep"},{"key":"16409_CR43","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1158\/1078-0432.CCR-14-1591","volume":"21","author":"B Alagesan","year":"2015","unstructured":"Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, et al. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res. 2015;21:396\u2013404. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1591.","journal-title":"Clin Cancer Res"},{"key":"16409_CR44","doi-asserted-by":"publisher","first-page":"67277","DOI":"10.18632\/oncotarget.11645","volume":"7","author":"H Ren","year":"2016","unstructured":"Ren H, Guo H, Thakur A, Zhang S, Wang T, Liang Y, et al. Blockade efficacy of MEK\/ERK-dependent autophagy enhances PI3K\/Akt inhibitor NVP-BKM120\u2019s therapeutic effectiveness in lung cancer cells. Oncotarget. 2016;7:67277\u201387. https:\/\/doi.org\/10.18632\/oncotarget.11645.","journal-title":"Oncotarget"},{"key":"16409_CR45","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1158\/1078-0432.CCR-11-2381","volume":"18","author":"T Shimizu","year":"2012","unstructured":"Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, et al. The clinical effect of the dual-targeting strategy involving PI3K\/AKT\/mTOR and RAS\/MEK\/ERK pathways in patients with advanced cancer. Clin Cancer Res. 2012;18:2316\u201325. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2381.","journal-title":"Clin Cancer Res"},{"key":"16409_CR46","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1634\/theoncologist.2019-0297","volume":"25","author":"A Bardia","year":"2020","unstructured":"Bardia A, Gounder M, Rodon J, Janku F, Lolkema MP, Stephenson JJ, et al. Phase Ib study of combination therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase inhibitor buparlisib in patients with advanced solid tumors with RAS\/RAF alterations. Oncologist. 2020;25:e160\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2019-0297.","journal-title":"Oncologist"},{"key":"16409_CR47","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/s41416-018-0322-4","volume":"119","author":"AM Schram","year":"2018","unstructured":"Schram AM, Gandhi L, Mita MM, Damstrup L, Campana F, Hidalgo M, et al. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K\/MTOR inhibitor voxtalisib in patients with advanced solid tumours. Br J Cancer. 2018;119:1471\u20136. https:\/\/doi.org\/10.1038\/s41416-018-0322-4.","journal-title":"Br J Cancer"},{"key":"16409_CR48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","volume":"3","author":"Q Li","year":"2022","unstructured":"Li Q, Li Z, Luo T, Shi H. Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy. Mol Biomed. 2022;3:47. https:\/\/doi.org\/10.1186\/s43556-022-00110-2.","journal-title":"Mol Biomed"},{"key":"16409_CR49","doi-asserted-by":"publisher","first-page":"e2313137120","DOI":"10.1073\/pnas.2313137120","volume":"120","author":"BR Daley","year":"2023","unstructured":"Daley BR, Vieira HM, Rao C, Hughes JM, Beckley ZM, Huisman DH, et al. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status. Proc Natl Acad Sci U S A. 2023;120:e2313137120. https:\/\/doi.org\/10.1073\/pnas.2313137120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16409_CR50","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1124\/jpet.122.001431","volume":"385","author":"M Jackson","year":"2023","unstructured":"Jackson M, Ahmari N, Wu J, Rizvi TA, Fugate E, Kim M-O, et al. Combining SOS1 and MEK inhibitors in a murine model of plexiform neurofibroma results in tumor shrinkage. J Pharmacol Exp Ther. 2023;385:106\u201316. https:\/\/doi.org\/10.1124\/jpet.122.001431.","journal-title":"J Pharmacol Exp Ther"},{"key":"16409_CR51","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4062\/biomolther.2021.145","volume":"30","author":"JE Lee","year":"2022","unstructured":"Lee JE, Woo MG, Jung KH, Kang YW, Shin S-M, Son MK, et al. Combination therapy of the active KRAS-targeting antibody inRas37 and a PI3K inhibitor in pancreatic cancer. Biomol Ther (Seoul). 2022;30:274\u201383. https:\/\/doi.org\/10.4062\/biomolther.2021.145.","journal-title":"Biomol Ther (Seoul)"},{"key":"16409_CR52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jconrel.2019.12.019","volume":"318","author":"MJ Kim","year":"2020","unstructured":"Kim MJ, Lee SJ, Ryu JH, Kim SH, Kwon IC, Roberts TM. Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment. J Control Release. 2020;318:98\u2013108. https:\/\/doi.org\/10.1016\/j.jconrel.2019.12.019.","journal-title":"J Control Release"},{"key":"16409_CR53","doi-asserted-by":"publisher","first-page":"eaay2174","DOI":"10.1126\/sciadv.aay2174","volume":"6","author":"S-M Shin","year":"2020","unstructured":"Shin S-M, Kim J-S, Park S-W, Jun S-Y, Kweon H-J, Choi D-K, et al. Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth. Sci Adv. 2020;6:eaay2174. https:\/\/doi.org\/10.1126\/sciadv.aay2174.","journal-title":"Sci Adv"},{"key":"16409_CR54","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1158\/0008-5472.CAN-23-0282","volume":"83","author":"AE Smith","year":"2023","unstructured":"Smith AE, Chan S, Wang Z, McCloskey A, Reilly Q, Wang JZ, et al. Tipifarnib potentiates the antitumor effects of PI3K\u03b1 inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via convergent inhibition of mTOR activity. Cancer Res. 2023;83:3252\u201363. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0282.","journal-title":"Cancer Res"},{"key":"16409_CR55","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00204-023-03440-4","volume":"97","author":"M Yu","year":"2023","unstructured":"Yu M, Chen J, Xu Z, Yang B, He Q, Luo P, et al. Development and safety of PI3K inhibitors in cancer. Arch Toxicol. 2023;97:635\u201350. https:\/\/doi.org\/10.1007\/s00204-023-03440-4.","journal-title":"Arch Toxicol"},{"key":"16409_CR56","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.2147\/DDDT.S142406","volume":"12","author":"G Krause","year":"2018","unstructured":"Krause G, Hassenr\u00fcck F, Hallek M. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des Devel Ther. 2018;12:2577\u201390. https:\/\/doi.org\/10.2147\/DDDT.S142406.","journal-title":"Drug Des Devel Ther"},{"key":"16409_CR57","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","volume":"27","author":"P Narayan","year":"2021","unstructured":"Narayan P, Prowell TM, Gao JJ, Fernandes LL, Li E, Jiang X, et al. FDA approval summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer. Clin Cancer Res. 2021;27:1842\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3652.","journal-title":"Clin Cancer Res"},{"key":"16409_CR58","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1182\/bloodadvances.2024013236","volume":"8","author":"PL Zinzani","year":"2024","unstructured":"Zinzani PL, Wang H, Feng J, Kim TM, Tao R, Zhang H, et al. CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma. Blood Adv. 2024;8:4866\u201376. https:\/\/doi.org\/10.1182\/bloodadvances.2024013236.","journal-title":"Blood Adv"},{"key":"16409_CR59","doi-asserted-by":"publisher","first-page":"204062072110060","DOI":"10.1177\/20406207211006027","volume":"12","author":"T Le","year":"2021","unstructured":"Le T, Jerel D, Bryan LJ. Update on the role of copanlisib in hematologic malignancies. Ther Adv Hematol. 2021;12:20406207211006027. https:\/\/doi.org\/10.1177\/20406207211006027.","journal-title":"Ther Adv Hematol"},{"key":"16409_CR60","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1813904.","journal-title":"N Engl J Med"},{"key":"16409_CR61","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","volume":"31","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Andr\u00e9 F, Yamashita T, Cerda H, Toledano I, Stemmer SM, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020;31:1001\u201310. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.001.","journal-title":"Ann Oncol"},{"key":"16409_CR62","doi-asserted-by":"publisher","first-page":"1034253","DOI":"10.3389\/fimmu.2022.1034253","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou H, Mu M, Zhao A, Cai Z, Li L, et al. Efficacy and safety of copanlisib in relapsed\/refractory B-cell non-Hodgkin lymphoma: a meta-analysis of prospective clinical trials. Front Immunol. 2022;13:1034253. https:\/\/doi.org\/10.3389\/fimmu.2022.1034253.","journal-title":"Front Immunol"},{"key":"16409_CR63","doi-asserted-by":"publisher","first-page":"21365","DOI":"10.1039\/d3ra02969g","volume":"13","author":"L Hong","year":"2023","unstructured":"Hong L, Li W, Li Y, Yin S. Nanoparticle-based drug delivery systems targeting cancer cell surfaces. RSC Adv. 2023;13:21365\u201382. https:\/\/doi.org\/10.1039\/d3ra02969g.","journal-title":"RSC Adv"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16409-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16409-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16409-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:05:11Z","timestamp":1785521111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16409-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16409"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16409-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated: The surname of the author \"Hugo Murua Escobar\" was updated from \"Escobar\" to \"Murua Escobar\"","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the German local authority: Landesamt f\u00fcr Landwirtschaft, Lebensmittelsicherheit und Fischerei Mecklenburg-Vorpommern (AZ: 1\u2013016\/21).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors give their consent to publish.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"812"}}